CHIKV is the prototype of Alphaviruses and it causes an acute febrile illness with rash, severely painful arthralgias, and sometimes arthritis. While CHIKV has first been identified in the 1950s in Africa, recent outbreaks of CHIKV in the islands of the Indian Ocean and particular in Italia have re-drawn attention to CHIKV. In the past CHIKV disease was considered self-limiting and non-fatal. However, a number of deaths on Reunion (Anonym, 2006) during the outbreak, which was affected directly or indirectly by CHIKV, have changed this view. To defeat CHIKV outbreaks diagnostic tools and anti CHIKV therapies are urgently needed. In this thesis, we generated tools to investigate CHIKV at the molecular level by serological tests. CHIKV was isolated from a German woman who was infected during her holidays on the Mauritius Island. To characterize this viral isolate the complete viral genome was amplified by PCR and molecular cloned. In order to analyse antibody responses of infected individuals some of the structural and non-structural genes were subcloned in bacterial expression vectors. The NSP2, proteinase, capsid, E1 and E2 were subsequently expressed in E.coli using purified successfully. In this thesis, the structural proteins were used to develop a screening test for anti-CHIKV antibodies in patient derived serum samples. These tests were evaluated with pre-characterized anti-CHIKV sera (30 samples) obtained from the BNI Hamburg and 100 serum samples from German blood donors used as negative controls. Immunoblotting analysis revealed that up to 77% of precharacterised positive sera could recognize the recombinant proteins and there were no detectable reactivity of CHIKV-negative German donor sera. The recombinant proteins were also recognized by 71.4% of positive sera in the newly established ELISA. In order to go further in analyses of the results, an in house IFA was performed. Positive sera (21 samples) were used. The results showed that all of them reacted positive, but this assay was less sensitive than the IFA from BNI. In comparison with the IFA result from BNI Hamburg, the results were not congruent in all test performed. This could be due to various drawbacks of the tests. A cross reaction in Alphaviruses and the different strains are mentioned as well as the denatured forms of the structural proteins. Besides the main structural proteins (E1, E2 and C), other proteins such as non-structural proteins, uncleaved precursor proteins could participate in the different outcomes of serological assays. In order to go further in the CHIKV diagnoses, the CHIKV recombinant proteins were applied to screen the anti-CHIKV antibodies in the Vietnamese population, who are considered to live in the high risk regions. In serological tests, 158 sera of Vietnamese donors were incubated with the recombinant proteins or the fixed CHIKV infected cells. The results showed that 24% of Vietnamese donor sera recognized the recombinant proteins in immunoblot assay, while 36% scored positive in the ELISA assay. In IFA, the sera considered positive were 11.4%. While some discrepancies in serological tests were found, these results showed that the ratio of CHIKV-positive sera seem to be equal to the other regions in the world, which are affected by CHIKV. It is suggested that CHIKV infection in Vietnam has been repeatedly misdiagnosed. This study cohort consisted only of samples originating from Hanoi area of Northern Vietnam, thus, future studies should expand to include samples from other Vietnam areas. To do this the various subtypes of the virus in the different regions should be isolated and the sequences of these viruses should be well characterized.

There is a disproportionate burden of disease (measured in daily-adjusted life years, or DALYs) in low-income countries. Much of this disparity is due to infectious diseases: 53% of DALYs in Africa are due to infectious diseases, compared with only 3% in the American continents. This disparity is largely due to differences in electrical and transport infrastructure as well as access to skilled personnel and monetary resources. Current diagnostic solutions are primarily designed for high-resource settings and therefore these solutions cannot be easily translated to a lower-resource setting. In order to tackle this health disparity, new solutions must be designed specifically for a lower-resource setting. In this dissertation, we take a translational approach to engineering appropriate diagnostics for resource-limited settings. First, we develop a handheld smartphone accessory to perform an assay similar to enzyme-linked immunosorbent assay (ELISA), traditionally a laboratory-based test. In 15 minutes, it provides an objective diagnostic readout important for minimal training, while using an average of 1.6mW of power and costing only $34. We further develop the device to provide a quantitative hemoglobin measurement simultaneously with an HIV immunoassay, for use in antenatal care screening. The multiplexing two assay types that are clinically relevant has the potential to streamline workflow. While specifications can be demonstrated in the laboratory, the true test of the device must be performed in the field. We brought our smartphone accessory to three health centers in Kigali, Rwanda to be used by healthcare workers with no prior experience in ELISA. After a short 30 minute training, the healthcare workers were able to obtain diagnostic results comparable to other immunoassays run under field conditions. With a simple and user-friendly design, we sought to further expand the usage of our device as a self-testing device, having patients test themselves. Lastly, we explore manufacturable thermoplastics as a material for a microfluidic diagnostic for nucleic acid detection. The sum of this work aims to gain insight into methods of design, testing, and implementation of translational design.

Abnormal T lymphocyte reactions in both autism and Alzheimer's disease (AD) have been reported. This research investigated the possibility that these abnormalities may involve circulating antithymic antibodies. Plasma samples from autistic patients, AD patients, and normal-matched controls were tested for reactivity against murine thymocytes. In the first of 3 studies results of the enzyme-linked immunosorbent assay (ELISA) were statistically significant for binding (P < 0.001) between antithymic antibodies in plasmas of AD patients and murine thymocytes. Binding (P < 0.05) in low dilutions (1/2.5 and 1/5} of autistic patient plasmas was also observed. In the second study, plasmas of neither autistic nor AD patients significantly inhibited DNA synthesis of thymic cells in the presence of interleukin-1 (IL-l} and phytohemagglutinin (PHA). In the third study, no significant increases (P > 0.05) in cytotoxic activities were detected using AD patient plasmas and both untreated and heat-treated autistic patient plasmas. After further testing, these heat-treated plasmas diluted 1/64 and 1/128 had increased cytotoxicities (P Therefore, circulating antithymic antibodies may be involved in abnormal T lymphocyte reactions in autism and AD. Since they probably do not act alone, future research should study these complex abnormalities using human thymocytes.

FAPα ist ein Membranglykoprotein mit Dipeptidyl-Peptidase- und Typ I Kollagenase-Aktivität, das eine wichtige Rolle im Rahmen des Gewebeumbaus und der Angiogenese spielt. Die Expression von FAPα wurde für eine Reihe von Geweben gezeigt. So konnte bereits gezeigt werden, dass FAPα nach Myokardinfarkt auf humanen kardialen Fibroblasten (HCF) verstärkt exprimiert wird. Ausgehend von der Erkenntnis, dass eine im Blut zirkulierende Form von FAPα, APCE, gefunden wurde, sollte in der vorliegenden Arbeit eine mögliche Assoziation des in HCF exprimierten FAPα mit dem zirkulierenden APCE untersucht werden. Hierfür wurden ebenfalls die Signalwege, die zur Induktion von FAPα führen, näher untersucht. Im Rahmen der vorliegenden Arbeit konnte gezeigt werden, dass das von humanen kardialen Fibroblasten exprimierte FAPα ebenfalls im Zellkulturüberstand nachgewiesen werden kann. Wie bereits beschrieben, führte eine Stimulation mit TGFβ1 zur Expression von FAPα. Diese ist abhängig von Smad-3 und konnte durch Zugabe des Inhibitors SB431542 blockiert werden. Auch Smad-2 scheint die FAPα-Expression zu beeinflussen. Ein Effekt von EGR-1, CTGF und TNFα auf die FAPα-Expression konnte hingegen nicht nachgewiesen werden. Darüber hinaus wurde im Rahmen der vorliegenden Arbeit ein ELISA zur Messung von humanem FAPα im Plasma erstmalig etabliert. In der Evaluation des ELISA wurden die Grenzwerte für die Detektion und Quantifizierung bestimmt, die Intra- und Intervariabilität des ELISAs berechnet und die Linearität der Wiederfindung von humanem rekombinantem FAPα bewertet, sowie die Stabilität von FAPα nach mehrfachen Einfrier-Auftau-Zyklen und nach der Lagerung bei verschiedenen Temperaturen evaluiert. Da hier nur kommerziell erwerbliche Materialien verwendet wurden, ist eine Anwendung durch Dritte leicht durchführbar. Es wurde weiterhin eine klinische Studie zur Messung der FAPα-Plasmaspiegel in 101 gesunden Blutspendern und 407 Patienten mit akutem Koronarsyndrom (ACS) sowie von 25 Patienten mit stabiler koronarer Herzerkrankung (KHK) durchgeführt. Hierbei konnten erstmals Referenzwerte für zirkulierendes FAPα im Plasma beschrieben werden. Die FAPα-Plasmaspiegel der gesunden Kontrollgruppe unterschieden sich nicht von denen der Patienten mit stabiler KHK. Bei Patienten mit akutem Koronarsyndrom war die FAPα-Konzentration im Vergleich mit den FAPα-Plasmaspiegeln der Kontrollgruppe hingegen signifikant erniedrigt. Auch zeigte sich bei den Patienten mit FAPα-Spiegeln im kleinsten Quartil eine erhöhte Mortalität. Die biologische Funktion von FAPα bzw. dessen mögliche Pathophysiologie im Rahmen eines ACS sowie die mit niedrigen FAPα-Spiegeln assoziierte Mortalität sind noch unklar und bleiben Gegenstand der weiteren Forschung. / FAPα is a membrane protein with dipeptidyl-peptidase and type-I-collagenase activity involved in angiogenesis and tissue repair. A number of cells and tissues including human cardiac fibroblasts (HCF) after myocardial infarction express FAPα. Due to the recent discovery of a circulating form of FAPα, APCE, a possible association between the cell-bound form of FAPα and APCE was studied in HCF. Furthermore, the signaling pathways that lead to an induction of FAPα were analyzed. It could be demonstrated that HCF shed FAPα, which can be detected in the cell culture supernatant. Moreover, in accordance with earlier results, FAPα expression is induced by TGFβ1. This is dependent on Smad-3 and could be blocked by the inhibitor SB431542. Additionally, Smad-2, but not EGR-1, CTGF or TNFα are involved in FAPα expression. Within this work an ELISA for the quantification of FAPα in human plasma was established and the limits of detection and quantification, the intra- and interassay variability and the linearity of recovery of human FAPα were determined. Furthermore, the stability of FAPα after multiple thaw-freeze-cycles or different storage conditions was evaluated. Because of the exclusive use of commercially available products, others could easily repeat this ELISA. FAPα plasma concentrations in 101 healthy blood donors, 407 patients with acute coronary syndrome (ACS) and in 25 patients with stable coronary artery disease were quantified by ELISA. This is the first time reference values for FAPα plasma levels could be derived. There was no significant difference between healthy donors and patients with stable coronary artery disease. However, compared to the healthy control group, FAPα levels were significantly lower in patients with ACS. Importantly, ACS patients with FAPα levels in the lowest quartile showed an increased mortality. The biological function of FAPα and its possible pathophysiological role in ACS are still unclear and remain the object of future studies.

Erlangen, Nürnberg, Universiẗat, Diss., 2007. / Enth. 1 Sonderabdr. aus: Journal of investigative dermatology ; 124. 2005. - Beitr. teilw. dt., teilw. engl.

Thesis (Ph. D.)--Ohio State University, 2006. / Title from first page of PDF file. Includes bibliographical references (p. 178-197).

To develop an assay to detect antibodies to Bacillus thuringiensis subsp. israelensis in mallard ducks, a growth curve was first established for the bacterium. The growth curve indicated that the crystal delta endotoxin would be best harvested from the rest of the cell material after 12 hours of growth. The delta endotoxin was solubilized in alkaline conditions followed by treatment with proteases or no treatment. The two differently treated delta endotoxins were purified by column chromatography. Fractions were assayed for duck erythrocyte lysis and cytotoxicity to a mosquito cell line. The proteolyzed sample gave four protein peaks with gel filtration, and the fourth peak containing biological activity was further separated into three protein fractions by anion exchange chromatography; two of the three showed biological activity. These two fractions contained 22 and 23 kD proteins species. The nonproteolyzed sample was separated into two protein fractions by gel filtration; only the first peak contained the biological activity. This fraction was further separated into two fractions by anion exchange chromatography; only the second fraction, containing a 28 kD protein, exhibited the activity. This fraction contained a 28 kD protein. However, the fractions containing 22 or 23 kD proteins originating from the proteolyzed sample showed the highest biological activity. Mallard ducks were repeatedly exposed to an aerosolized commercial preparation of the organism. Sera were collected periodically and tested for the antibody by an enzyme-linked immunosorbent assay (ELISA). Those toxic antigens containing 22 or 23 kD proteins were unsuitable for the assay. The exposed ducks were found to produce antibodies against the first fraction from anion exchange chromatography of the proteolyzed sample. The antibody titres increased as the number of exposures increased. The results suggest that ELISA is applicable for detecting antibodies against B.t.i. in wild ducks using the fraction containing a 50 kD protein. / Graduation date: 1992

Graduation date: 1992

Electrospinning is a technique to achieve nanometer scale fibers. Similar to the conventional spin methods of making fabric, the viscous polymer solution is ejected from a spinneret; stretched and solidified in the air, the solution forms the fibers. The different part of electrospinning among others is that the fibers are driven by the electrostatic force, which induces the repulsion inside the liquid and further reduces the diameter. The resultant product is a non-woven membrane, which is porous; and the pore size is around several nanometers to a micrometer wide. In this work, the relationship between the diameter of electrospun silica fibers, experimental parameters such as concentration and voltage, and between pore size of the fiber membrane and experimental time were studied. Materials used in the process are Polyvinylpyrrolidone (PVP), butanol and spin-on-glass coating solution, which act as polymer carrier, solvent, and silica-precursor, respectively. Polymer/silica precursor composite fibers were ejected from the needle of a plastic syringe when an electrical field, as high as several kV/cm, was applied. Then silica fibers were achieved by baking the composite ones at 773 oK for 12 h. Electrospun silica nanofibers were characterized as a function of polymer solution parameters. The calcined fibers were examined by using a field emission scanning electron microscope. The results showed that the fiber diameters decrease with decreasing proportion of polymer and silica precursor, and increase with a higher electric field. Pore sizes, defined as the grid areas enclosed by fibers on nearby layers, were also examined and showed no time-dependent tendency when the electrospin time was between 1-5 min. Fiber membranes were then used as the platform for protein detection. The results were compared with the control, which used glass slides as the platform. The results make it possible to make a more sensitive biosensing device.

Thesis (M. Med. Sc.)--University of Hong Kong, 2001. / Includes bibliographical references (leaves 41-49).